MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
529.61
+14.27
+2.77%
Opening 11:39 08/11 EDT
OPEN
516.97
PREV CLOSE
515.34
HIGH
533.11
LOW
512.84
VOLUME
162.45K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
342.73
MARKET CAP
12.24B
P/E (TTM)
-41.1498
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDGL last week (0803-0807)?
Weekly Report · 1d ago
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Simply Wall St · 2d ago
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach
Seeking Alpha · 6d ago
Walmart downgraded, Palantir upgraded: Wall Street’s top analyst calls
TipRanks · 08/04 13:41
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Benzinga · 08/04 11:46
Madrigal Pharmaceuticals Price Target Announced at $605.00/Share by Wolfe Research
Dow Jones · 08/04 09:39
Madrigal Pharmaceuticals Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 08/04 09:39
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target
Benzinga · 08/04 09:29
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.